title: [Tailored therapy for rheumatic disease within reach].
abstract: Personalised medicine has the potential to increase therapeutic effectiveness, reduce side effects and lower cost. This approach has recently taken off in oncology where different malignancies may be treated with specific drugs based on genetic biomarkers or other tumour characteristics. This type of tailored therapy could also be developed for immune-mediated inflammatory disease, for which rheumatoid arthritis (RA) may serve as a prototype. While novel treatments are able to halt or even prevent disease progression, not all RA patients respond, and stratification of patient groups is needed. The identification of biomarkers predictive of the clinical response to specific treatments in subsets of patients may soon become reality in a variety of diseases.
authors.affiliation: Academisch Medisch Centrum, afd. Klinische Immunologie en Reumatologie, Amsterdam, the Netherlands. p.p.tak@amc.uva.nl
authors.forename: Lisa G M
authors.initials: LG
authors.lastname: van Baarsen
authors.forename: Beatrijs M
authors.initials: BM
authors.lastname: Lodde
authors.forename: Paul P
authors.initials: PP
authors.lastname: Tak
mesh_terms: D000911:Antibodies, Monoclonal / Q000191:economics / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000191:economics / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000191:economics; D015415:Biomarkers; D003362:Cost-Benefit Analysis; D018450:Disease Progression; D006801:Humans; D011379:Prognosis; D019057:Quality-Adjusted Life Years; D018124:Receptors, Tumor Necrosis Factor / Q000008:administration & dosage / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D015415:Biomarkers; D018124:Receptors, Tumor Necrosis Factor